» Articles » PMID: 19318991

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-type ADHD in a Multisite Study

Abstract

Objectives: To determine any long-term effects, 6 and 8 years after childhood enrollment, of the randomly assigned 14-month treatments in the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA; N = 436); to test whether attention-deficit/hyperactivity disorder (ADHD) symptom trajectory through 3 years predicts outcome in subsequent years; and to examine functioning level of the MTA adolescents relative to their non-ADHD peers (local normative comparison group; N = 261).

Method: Mixed-effects regression models with planned contrasts at 6 and 8 years tested a wide range of symptom and impairment variables assessed by parent, teacher, and youth report.

Results: In nearly every analysis, the originally randomized treatment groups did not differ significantly on repeated measures or newly analyzed variables (e.g., grades earned in school, arrests, psychiatric hospitalizations, other clinically relevant outcomes). Medication use decreased by 62% after the 14-month controlled trial, but adjusting for this did not change the results. ADHD symptom trajectory in the first 3 years predicted 55% of the outcomes. The MTA participants fared worse than the local normative comparison group on 91% of the variables tested.

Conclusions: Type or intensity of 14 months of treatment for ADHD in childhood (at age 7.0-9.9 years) does not predict functioning 6 to 8 years later. Rather, early ADHD symptom trajectory regardless of treatment type is prognostic. This finding implies that children with behavioral and sociodemographic advantage, with the best response to any treatment, will have the best long-term prognosis. As a group, however, despite initial symptom improvement during treatment that is largely maintained after treatment, children with combined-type ADHD exhibit significant impairment in adolescence. Innovative treatment approaches targeting specific areas of adolescent impairment are needed.

Citing Articles

Long-term effect of pharmacological treatment on academic achievement of Norwegian children diagnosed with ADHD: a target trial emulation.

Varnet Perez T, Overgaard K, Frigessi A, Biele G Int J Epidemiol. 2025; 54(2).

PMID: 39955105 PMC: 11829807. DOI: 10.1093/ije/dyaf010.


Attention-Deficit/Hyperactivity Disorder Symptoms and Later E-Cigarette and Tobacco Use in US Youths.

McCabe S, Pasman E, Wilens T, Boyd C, Veliz P, McCabe V JAMA Netw Open. 2025; 8(2):e2458834.

PMID: 39932711 PMC: 11815522. DOI: 10.1001/jamanetworkopen.2024.58834.


"They are just as different as the rest of us" - a focus group study of primary teachers' perceptions of children with ADHD who struggle socially.

Munch M, Hjelen Stige S, Adolfsdottir S, Sorensen L, Osnes B Int J Qual Stud Health Well-being. 2025; 20(1):2465215.

PMID: 39930964 PMC: 11816612. DOI: 10.1080/17482631.2025.2465215.


Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records.

Young J, Powell R, Powell A, Welling L, Granata L, Saal J BMC Psychiatry. 2025; 25(1):12.

PMID: 39754122 PMC: 11697907. DOI: 10.1186/s12888-024-06446-z.


Digital Homework Support Program for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Protocol for a Randomized Controlled Trial.

Gollier-Briant F, Ollivier L, Joalland P, Mouchabac S, Leray P, Bonnot O JMIR Res Protoc. 2024; 13:e44553.

PMID: 39571155 PMC: 11621713. DOI: 10.2196/44553.


References
1.
Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak J . Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J Atten Disord. 2006; 9(3):465-75. DOI: 10.1177/1087054705283881. View

2.
Molina B, Flory K, Hinshaw S, Greiner A, Eugene Arnold L, Swanson J . Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry. 2007; 46(8):1028-1040. DOI: 10.1097/chi.0b013e3180686d96. View

3.
Arnold L, Abikoff H, Cantwell D, Conners C, Elliott G, Greenhill L . National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Arch Gen Psychiatry. 1997; 54(9):865-70. DOI: 10.1001/archpsyc.1997.01830210113015. View

4.
Shaffer D, Fisher P, Lucas C, Dulcan M . NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry. 2000; 39(1):28-38. DOI: 10.1097/00004583-200001000-00014. View

5.
Swanson J, Hinshaw S, Eugene Arnold L, Gibbons R, Marcus S, Hur K . Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007; 46(8):1003-1014. DOI: 10.1097/CHI.0b013e3180686d63. View